The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major advance against metastatic pancreatic cancer.

Presentato all’ASCO, daraxonrasib ha mostrato risultati importanti nei pazienti con tumore del pancreas avanzato. Una possibile svolta, anche se l’arrivo in Europa richiederà tempo

The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major advance against metastatic pancreatic cancer.